Kornimate/medical-research-clean huggingface dataset:
cardiac safety of lansoprazole and domperidon combination

Conditions: GERD; Cardiac Event; Safety Issues

Summary: the aim of current study is to compare safety and efficacy of lansoprazole/domperidone 30/30 mg sustained release capsules (brand name: duolans) and lansoprazole 30 mg micropellet capsules (brand name: lasotab) in gerd patients in terms of cardiac safety.


Eligibility criteria:
inclusion criteria: * gerd patients with bmi 18-33 kg/m2 * patients with esophagitis class a-b according to los angeles classification exclusion criteria: * patients whose long qt syndrome risk score \> 3. * patients with family history of short or long qt syndrome. * patients with barrett's stricture, gastric outlet obstruction, malignancy, gastrointestinal system bleeding or any other upper gastrointestinal system pathology. * patients whose hiatus hernia is \> 3 cm. * patients with uncontrolled or insulin dependent diabetes mellitus, symptomatic gallbladder stone, active or unhealed stomach or duodenum ulcer, zollinger-ellison syndrome, primary esophagus motility disorder, pancreatitis, inflammatory bowel disease, severe lung disease, chronic liver disease, uncontrolled kidney impairment, cancer (except skin cancer except melanoma), cerebrovascular disease, epilepsy. * patients with history of heart failure, ventricular tachycardia, ventricular fibrillation, cardiac arrest, torsades de pointes, bradycardia, sinus node dysfunction, heart attack, long qtc (\>460 ms). * patients taken ppis or h2-blockers within 7 days and prokinetic drugs within 3 days before entering the study. * patients with major psychiatric disease. * alcoholism and drug use. * patients with pathologic laboratory tests; hemogram, sedimentation, crp, thyroid functions tests, liver enzymes. * malabsorption. * immunosuppressive patients. * patients taken cortisone. * patients taken other drugs that prolong qt interval. * patients taken drugs that need gastric acid for optimal absorption; ketoconazole, iron salts, digoxin, ampicillin esters, anticoagulants, antineoplastic agents, prostaglandin analogues, sucralfate, atazanavir, theophylline, tacrolimus, fluvoxamine, rifampisin, nefazodone and aprepitant. * patients taken drugs carried with p-glycoprotein, indicated for heart diseases, aids/hiv or infection treatment. * pregnancy or breast-feeding. * patients taken drugs that may affect gastrointestinal system motility or acid release. * history of abdominal surgery (hysterectomy, abdominal hernia repair, caesarean cases may be included; cholecystectomy have to be excluded). * patients with hypocalcemia and hypercalcemia * patients taken nsaii drugs (paracetamol may be used up to 2 gr/day). * patients taken antidepressants. * hypersensitivity to study drugs.
laparoscopic ovarian cystectomy of endometrioma vs deroofing and ovarian reserve

Conditions: Endometrioma

Summary: the purpose of this study is to evaluate the impact of laparoscopic ovarian cystectomy versus laparoscopic cyst deroofing on ovarian reserve measured by serum levels of anti mullerian hormone and antral follicle count in patients with endometriomas.

one of the major concerns about excision of endometriomas is their negative effect on ovarian reserve because of follicle loss, removal of endometriomas has been associated with poorer performance in ivf procedures, and decreased ovarian volumes have also been reported after surgery.ovarian reserve is defined as the functional potential of the ovary which reflects the number and quality of the follicles left in the ovary, and is well-correlated with the response to ovarian stimulation using exogenous gonadotrophin. over the years, various tests and markers of ovarian reserve have been reported; the static tests include serum markers, such as basal fsh, inhibin-b and anti-mullerian hormone (amh), and ultrasonographic markers, such as ovarian volume and antral follicle count.this study will include 122 patients aged between 18 and 35 years who have been diagnosed with endometrioma (unilateral or bilateral) and they are candidates for laparoscopic surgery. they will be selected according to inclusion and exclusion criteria.they will be randomized into two study groups, one study group will undergo laparoscopic ovarian cystectomy, the other study group will undergo laparoscopic cyst deroofing.amh,afc and ovarian volume will be measured pre-operative and post-operative.

Eligibility criteria:
inclusion criteria: 1. age from 18-35 year 2. regular menstrual cycles. 3. endometrioma (unilateral or bilateral) diagnosed by transvaginal ultrasound with diameter ≥ 3 cm. exclusion criteria: 1. any previous ovarian surgery. 2. evidence of polycystic ovary syndrome according to rotterdam criteria -two of three of: * oligo- or chronic anovulation. * clinical and/or biochemical signs of hyperandrogenism. * polycystic ovaries. 3. evidence of premature ovarian failure diagnosed by follicle stimulating hormone level ≥40 iu/l 4. any endocrinal disease affecting ovarian function e.g. thyroid dysfunction, hyperprolactinemia. 5. previous hormonal medications e.g. oral contraceptive pills, gonadotropin-releasing hormone analogue within the last 3 months before surgery. 6. any suspicious findings of ovarian malignant diseases diagnosed by transvaginal ultrasound. 7. contraindication to surgery.

Keywords: laparoscopy amh afc endometrioma ovarian reserve ovarian cystectomy ovarian cyst deroofing
efficacy of teas on postoperative pain and recovery in patients undergoing hepatectomy

Conditions: Liver Cancer

Summary: the purpose of this study is to access the effect of transcutaneous electrical acupoint stimulation on postoperative pain in patients undergoing hepatectomy

patients who meet the enrollment criteria will be randomized 1:1 to either the transcutaneous electrical acupoint stimulation (teas#or the sham groups. in the teas group, the acupoints are bilateral neiguan (pc6) , hegu(l14), yanglingquan(gb34), zusanli(st 36) and renying(st9) acupoints. patients will receive teas 30min before anesthesia until being discharged from the post-anaesthesia care unit (pacu). the same treatment for 30 min will be performed on the 1st, 2nd and 3rd days after surgery.the stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient. patients in the sham group will receive electrode attachment but without stimulation.

Eligibility criteria:
inclusion criteria: age 18-80 years old; asa physical status classⅰ-ⅲ; patients scheduled for elective hepatectomy. exclusion criteria: have a history of epilepsy; rash or local infection over the acupoint stimulation skin area; pregnancy or breastfeeding; mental retardation, psychiatric, or neurological disease; inability to comprehend the numeric rating scale (nrs); implantation of a cardiac pacemaker, cardioverter, or defibrillator; chronic opioid use; metastases in other organs;
a study to demonstrate the efficacy of gsk biologicals' influenza vaccine in adults

Conditions: Influenza

Summary: the purpose of this study is to demonstrate the efficacy of gsk biologicals' influenza vaccine (fluarix™) administered intramuscularly in adults.


Eligibility criteria:
inclusion criteria: * a male or female age between 18 and 64 years at the time of the first vaccination. * non-childbearing female exclusion criteria: * use of non-registered products * pregnancy * hypersensitivity to a previous dose of influenza vaccine * acute disease at the time of enrolment/vaccination. * history of allergy or reactions likely to be exacerbated by any component of the vaccine * administration of any other influenza vaccine for the season 2006-2007 * chronic disorders of the pulmonary or cardiovascular system, including asthma. * administration of immune-modifying drugs * administration of immunoglobulins and/or any blood products * history of requiring regular medical follow-up or hospitalization during the preceding year because of chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, asthma or immunosuppression (including immunosuppression caused by medications or by human immunodeficiency virus)

Keywords: influenza vaccine prophylaxis influenza vaccine
music and local anesthesia during dermatologic procedures

Conditions: Pain; Anxiety

Summary: the goal of the study is to determine the effect of classical music on participants pain and anxiety associated with lidocaine administration during routine standard of care dermatologic procedures.

the study is a randomized, unblinded, prospective, single center clinical trial. the purpose of the study is to determine the effect of a music intervention in reducing anxiety and pain from local anesthesia administration in subjects undergoing a routine, standard of care dermatologic procedure. the study population will consist of 100 adult subjects undergoing a dermatologic procedure on the head and neck. subjects will be randomized 1:1 into either the placebo or music intervention group. individuals randomized into the placebo (p) group will undergo a set of standardized steps prior to local anesthesia injection. other factors such as skin preparation technique, needle size, anesthesia temperature, use of unbuffered solution, needle angle and approximate depth of injection will remain standardized. individuals randomized into the music intervention (mi) group will undergo the same set of standardized steps and then be played frederic chopin's piano sonatas through a headphone device prior to injection. after local anesthesia administration, subjects in both treatment arms will be asked to fill out a demographics, pain and anxiety questionnaire.

Eligibility criteria:
inclusion criteria: * subjects undergoing dermatologic procedures on the head and neck * ages 18-89 years old * english speaking * willingness and the ability to understand and provide informed consent exclusion criteria: * subjects who are allergic to lidocaine * history of bleeding tendency or coagulopathy * pregnant or lactating * active skin infection in the treatment area * active cancer diagnosis * unable to understand the protocol or give informed consent * any other condition, in the professional opinion of the investigator, that would potentially affect response or participation in the clinical study, or would pose as an unacceptable risk to the subject

Keywords: pain anxiety lidocaine local anesthesia dermatologic procedures dermatology
rescue thrombolysis for medium vessel occlusion (rescue-tnk)

Conditions: Stroke, Ischemic

Summary: the best reperfusion strategy for medium-sized vessel occlusion (mevo) is not well established. given the proven treatment effect of intra-arterial thrombolysis in patients with large vessel occlusion (lvo), the investigators hypothesized that intra-arterial tenecteplase (tnk) could increase the recanalization rate of mevo and thus improve clinical outcome. the current study aimed to explore the safety and efficacy of intra-arterial tnk in patients with mevo.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years; 2. medium vessel occlusion (mevo), referring to m2-3 of mca; a1-3 of aca; p1-3 of pca; pica, aica or sca (including primary, distal embolism in the same region after thrombectomy or concurrent embolism in other regions). * primary mevo as detected by the first dsa examination or secondary mevo after mechanical thrombectomy for large vessel occlusion; * mevo causes neurological deficits in motor strength, language, vision etc; * endovascular mechanical thrombectomy cannot be performed as assessed by the investigator; * absence of parenchymal hematoma on ct images performed in the angio suite. 3. within 24 hours from symptom onset; 4. signed informed consent by patient or patient's legally authorized representative. exclusion criteria: 1. patients with completed infarction in the territory of the mevo on non-contrast ct; 2. patients with intracranial hemorrhage; 3. coagulation disorders, tendency for systemic hemorrhagic, thrombocytopenia (\<100,000/mm3); 4. severe hepatic or renal dysfunction, increase in alt or ast (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis; 5. after mechanical thrombectomy, severe and sustained (\> 5 minutes) uncontrolled hypertension (systolic blood pressure over 180mmhg or diastolic blood pressure over 105 mmhg); 6. patients with contraindication or allergy to any ingredient of study medication; 7. pregnancy, plan to get pregnant or active lactation; 8. the estimated life expectancy is less than 6 months due to other serious diseases; 9. other conditions unsuitable for this clinical study as assessed by researcher.
benefit of pharyngeal and oesophageal ph-impedance of patients with high suspicion of laryngopharyngeal reflux

Conditions: Laryngopharyngeal Reflux; Oesophageal pH-impedance

Summary: laryngopharyngeal reflux (lpr) is the retrograde movement of gastric contents into the larynx, pharynx and upper aerodigestive tract. the symptoms and manifestations are very changeable and non specific. pharyngeal and oesophageal ph-impedance may help to detect these reflux and to identify patients with abnormal lpr. to compare and describe the results of pharyngeal and oesophageal ph-impedance of patients with high suspicion of laryngopharyngeal reflux, with the results of healthy patients.

this is a monocentric, prospective descriptive study. patients will be recruited in otolaryngology and gastroenterology departments of bordeaux teaching hospital. a first clinical, endoscopic and ph-impedance evaluation will be made, after at least 15 days of interruption of any proton pump inhibitors (ppi). after 8 weeks' treatment by double ppi doses (esomeprazole 40 mg bid), another clinical and ph-impedance evaluation will be realized. the characteristics of the patients who respond to the treatment will be compared to non responders. the subjects will also have an initial laryngoscopy, an oesophageal manometry allowing the location of the lower sphincter of the oesophagus and the upper sphincter of the oesophagus for positioning the catheters.

Eligibility criteria:
inclusion criteria: * age : 18 to 80 years old. * written consent * laryngopharyngeal symptoms (dysphonia, and/or globus and/or sensation, and/or pharyngeal pain, and/or cough) for 3 months at least. * no ppi for at least 15 days * social security affiliation exclusion criteria: * sinusitis or chronic rhinitis (in the previous year) * laryngeal trauma, tracheotomy or pharyngolaryngeal surgery * pregnancy or absence of efficacy contraception * breast feeding * history of gastrointestinal pathology, diabetes, neurological condition * cardio-vascular history requiring the taking of plavix * esomeprazole contraindication or intolerance
analysis of the motion activity manual wheelchair users

Conditions: Spinal Cord Injuries

Summary: currently, there is no system in place to allow manual wheelchair users to know their quantities of movement activities and the intensity of effort to be provided during these propulsion movements. based on recent work by routhier et al. in 2017, and in light of the scientific literature related to wheelchair propulsion, it would seem appropriate to validate the use of inertial units as tools to quantify and categorize the intensity of manual wheelchair propulsion.

the investigator hypothesize that an inertial unit positioned on the wheelchair wheel has the same detection rate of the propulsion cycle as a dynamometric wheel (step 1). in addition, the investigator hypothesize that the categorization of the detected propulsion cycle as a function of force intensity is similar between the angular deceleration of the wheel during propulsion calculated from the inertial unit and the external mechanical power calculated from a dynamometric wheel (step 2).

Eligibility criteria:
inclusion criteria: for the healthy user group volunteers: * men or women over 18 years of age, * an experience of at least 2 hours using the manual wheelchair, * subject who has signed an informed and written consent, * affiliation to a social security system. for the spinal cord injured user group: * men or women over 18 years of age, * injured medullary users of manually propelled wheelchairs for daily locomotion (at least 30/100 at wst on travel items), * subject who has signed an informed and written consent, * affiliation to a social security system. exclusion criteria: * patient refusing to participate in the study, * manual wheelchair users with propulsion assistance system, * major cognitive disorders, * unbalanced cardiovascular disease, * pressure sores and unhealed palm lesions, * asthma to effort, * progressive etiologies: tumor, infectious, inflammatory and associated - - pathologies: head trauma, amputation, * patient under guardianship or curatorship, * pregnant or breastfeeding woman.

Keywords: detection rate of propulsion cycles
screening strategies for people with a high risk of anal cancer

Conditions: Neoplasms; HPV-Related Anal Squamous Cell Carcinoma

Summary: the goal of the proposed research is to 1) examine the performance of emerging screening methods for anal high-grade squamous intraepithelial lesion (ahsil), a precancerous condition of anal cancer, among minorities with a high risk of anal cancer and 2) characterize dna methylation, immunologic response, and social determinants associated with ahsil.

anal cancer, caused by persistent infection with high-risk human papillomavirus (hrhpv), is typically preceded by anal high-grade squamous intraepithelial lesions (ahsil). the incidence and mortality of advanced anal cancer has been increasing in the u.s., with the greatest burden of disease and mortality in individuals living with hiv. the study is important because the incidence of anal cancer is particularly high among certain groups; health disparity further contributes to this high risk among minorities. findings will provide much-needed evidence for anal cancer screening strategies to reduce health disparities, improve screening outcomes, and decrease the incidence of anal cancer among high-risk minorities. the study population includes black or latinx, males - men having sex with men (msm) only - and females with a known history of high-grade lower genital tract neoplasia. the study procedures include filling out self-reported questionnaires and collecting biosamples for study-related assays. hra is part of the standard clinic procedure for this group of participants. collected biosamples will be banked for future research use. in-person or remote signed consent may occur for the study.

Eligibility criteria:
inclusion criteria: * 30 years of age and older * identifies as black or latinx, * males (msm only) and females with a known history of high-grade lower genital tract neoplasia (lgtn), zubrod performance status of 0-2; * women with human papillomavirus (hpv) related cervical, vaginal, or vulvar high-grade precancer or cancer exclusion criteria: * patients treated for ahsil less than 6 months before screening, * history of anal cancer and pregnant women.

Keywords: cancer hiv screening
assessment of routine oral screening programs for new prisoners

Conditions: Oral Disease

Summary: in 2018, 10 detention centers in france will start organisational programs to improve the quality of screening of oral diseases, relatively to french recommendations, among new prisoners in france. our study aims 1) to assess the prevalence and nosology of oral diseases ; 2) to describe the care pathway of participants during their stay in the detention center where they were included ; 3) to assess the cost of care per patient, from a societal perspective, using a top-down method.


Eligibility criteria:
inclusion criteria: * new prisoners * fluent french language exclusion criteria: * adult guardianship
genotype-phenotype correlation and pathogenic mechanism in hereditary ataxia

Conditions: Hereditary Ataxia

Summary: the investigators aimed to find appropriate biomarkers such as serum neurofilament light chain in reflecting disease severity in hereditary ataxia from a large cohort during long-term follow-up. the disease severity is indicated by clinical scales and brain mri tests.


Eligibility criteria:
inclusion criteria: * genetically diagnosed as spinocerebellar ataxia exclusion criteria: * deny follow-yp
contingency management of psychostimulant abuse in the severely mentally ill

Conditions: Drug Abuse; Schizophrenia; Bipolar Disorder; Major Depressive Disorder

Summary: the purpose of this study is to determine the effectiveness of a behavioral treatment, contingency management, in reducing stimulant use in persons with serious mental illness.

this study will evaluate the efficacy of a twelve week contingency management (cm) intervention for treating psycho-stimulant substance abuse when delivered in the context of a community mental health center (cmhc) setting for adults suffering from serious mental illness (smi). the cm paradigm to be used is one which has been shown effective in several recent large clinical trials, using the variable magnitude of reinforcement procedure. the reinforcers will be vouchers or actual items useful for day to day living in this population. two hundred smi participants with co-occurring stimulant disorders will be recruited from a large urban cmhc and randomized to receive either the active cm paradigm plus treatment as usual (tau), or tau which will include the delivery of reinforcement for study involvement (reinforcement that is not contingent on drug abstinence). the primary outcome is change in psycho-stimulant use (methamphetamine, amphetamine and/or cocaine). secondary outcomes include: changes in use of other illegal drugs or alcohol; changes in cmhc treatment adherence and follow-through; changes in psychiatric symptoms, quality of life, and community outcomes (homelessness, incarcerations, etc.). additional outcomes to be measured include changes in drug craving, stage of change, nicotine use, and hiv risk status. the study involves two phases, the 12 week treatment phase, where cm and control treatments are delivered, as well as a 3 month follow up phase.

Eligibility criteria:
inclusion criteria: * enrolled patient at community psychiatric clinic (cpc), a large mental health center in urban seattle, washington; * between 18 and 65 years of age; * diagnosis of of methamphetamine, amphetamine(illegal), or cocaine dependence or abuse; * cpc medical record diagnosis of schizophrenia, schizoaffective disorder, bipolar i or ii, or recurrent major depressive disorder * stimulant drug use one month before enrollment; * ability to understand written and spoken english; * cpc clinical case manager must affirm the potential participant's ability to provide informed consent and clinical appropriateness (i.e., safety/severity of mental/substance/ physical health) to participate in the study. exclusion criteria: * any medical/psychiatric condition, or severity of that condition, that, in the opinion of dr. ries, the pi, would compromise safe study participation * chart defined organic brain disorder or dementia; * current participation in a methadone maintenance program; * any other circumstances that in the pi's opinion precludes safe study participation.

Keywords: stimulant abuse drug abuse schizophrenia bipolar disorder major depressive disorder contingency management psychosocial treatment